BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin(tm) (formerly Bio-E-Gel®) (estradiol gel) for the treatment of vasomotor symptoms in menopausal women, and LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD). Elestrin was just approved by the FDA. Elestrin represents the lowest dose of estradiol approved by the FDA for vasomotor symptoms. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at: www.biosantepharma.com.

Category:

News & Politics

Tags:

• bio
• sante
• pharma
• stock
• money
• power
• finance
• dollar
• exchange
• hormone
• therapy
• treatment
• wall
• street
• ceo
• bull